KeyBanc analyst Matthew Gillmor lowered the firm’s price target on Acadia Healthcare (ACHC) to $55 from $65 and keeps an Overweight rating on the shares. The firm notes Q1 results were solid, highlighted by a 2% EBITDA beat and stable-to-improving SS volumes. Acadia’s EBITDA appears to have stabilized post second half of 2024 challenges, and KeyBanc thinks Q1 results put the company in a good position to hit the required second half of the year ramp.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare price target lowered to $28 from $35 at Barclays
- Acadia Healthcare: Resilient Performance and Strategic Expansion Justify Buy Rating
- Acadia Healthcare Reports Q1 2025 Results and Growth Plans
- Positive Outlook for Acadia Healthcare: Strong Q1 Performance and Strategic Initiatives Drive Buy Rating
- Acadia Healthcare: Strong Financial Performance and Growth Prospects Amidst Adjusted Price Objective